November 18, 2009 08:30 ET

ONE Bio Reports Third Quarter 2009 Results

MIAMI, FL--(Marketwire - November 18, 2009) - ONE Bio, Corp. ("ONE" or the "Company") (formerly ONE Holdings, Corp.) (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced results for the quarter ended September 30, 2009.

The Company recently changed its name to ONE Bio, Corp. from ONE Holdings, Corp. to more accurately reflect its focus on health-related and organic products. The company experienced continued strong demand for its products. ONE also continues to build momentum around its planned expansion.

Third Quarter Results:

Third quarter 2009 revenue was up 57.8% to $4,157,806 compared to $2,634,409 for the same period a year ago. Operating Income was up 22.4% to $1,491,037 compared to $1,218,137 for the same period last year. Net Profit was up 16.2% to $849,970 compared to $731,314 for the same quarter last year.

YTD 2009 revenue now reaches $8,625,175 compared to $7,501,285 for the first three quarters last year, an increase of 15.0%. YTD 2009 operating income and net income now reach $3,472,726 and $2,072,065 respectively.

Pro Forma Results with Recently Completed Acquisitions:

The Company completed the acquisition of its current operating businesses during the third quarter of this year. As a result only partial operating results from the acquired businesses are reflected in the Company's third quarter financials. In an effort to reflect a more meaningful picture of the actual financial performance of the acquired businesses, the Company has prepared pro-forma financial results on a consolidated basis showing the performance of its operating businesses as if the Company owned them from 2008 through 2009 YTD. Investors can review these results in note #8 to the financial statements recently filed by the Company in the latest 10Q.

Performance highlights include:

Third quarter 2009 (pro-forma) revenue was up 71.7% to $9.4 million compared to $5.5 million for the same period a year ago. Operating Income was up 119.6% to $2.7 million compared to $1.2 million for the same period last year. Net Income was up 332.8% to $1.7 million compared to $385k for the same quarter last year.

YTD 2009 (pro-forma) operations have generated combined revenues of $25.9 million compared to $23.3 million for the first three quarters last year, an increase of 11.4%. YTD 2009 (pro-forma) the Company generated operating income and net income of $7.7 million and $5.1 million compared to $6.4 million and $4.0 million respectively.

Additionally, management anticipates further operations improvement as:

--  Consolidation of recently concluded acquisitions is completed;
--  Launch of over the counter health products occurs; and
--  Company completes the acquisition of additional strategically targeted
    synergistic businesses providing profitability and strong cash flows and
    further allowing the Company to expand its product portfolio and achieves
    greater vertical integration.

PRO-FORMA        For the 3 month        For the 9 month       For 12 months
 RESULTS      Period Ended Sept 30,   Period Ended Sept 30,   Ended Dec 31,
                 2009       2008          2009        2008         2008

  Revenues   $ 9,393,907 $ 5,470,834 $ 25,913,885 $ 23,266,582 $ 34,839,128
  Cost of
   goods sold  5,186,606   2,920,804   14,857,339   13,918,331   20,534,124
             -----------  ---------- ------------ ------------ ------------
   profits     4,207,301   2,550,030   11,056,546    9,348,251   14,305,004
   Expenses    1,535,934   1,333,463    3,314,938    2,616,510    3,835,126
             -----------  ---------- ------------ ------------ ------------
   Income      2,671,366   1,216,567    7,741,607    6,731,741   10,469,878
   expenses      107,015     113,356      162,283      336,798       92,539
             -----------  ---------- ------------ ------------ ------------
   taxes       2,564,351   1,103,211    7,579,324    6,394,943   10,377,339
   for income
   taxes        -692,018    -568,923   -1,973,780   -1,873,964   -2,679,642
   interest     -203,257    -148,678     -497,857     -500,639     -656,794
             -----------  ---------- ------------ ------------ ------------
  Net income $ 1,669,076 $   385,610 $  5,107,687 $  4,020,340 $  7,040,903
             =========== =========== ============ ============ ============
  Pre-split  $      0.01 $      0.00 $       0.03 $       0.03 $       0.05
             =========== =========== ============ ============ ============
  Post-split $      0.05 $      0.01 $       0.16 $       0.13 $       0.23
             =========== =========== ============ ============ ============

"We are very pleased with what our team has accomplished since taking control of ONE five months ago. The strong market conditions which currently exist in the Asia Pacific region have fueled a strong demand for our products. When coupling that demand with our ability to execute on our recently completed acquisition strategy, our Company's financial position has been transformed. ONE Bio now has in excess of $46 million in assets on its balance sheet with over $29 million in shareholders' equity. We have integrated money generating businesses in the highly sought-after organic products, herbal and chemical extracts and natural and health supplements market segments. ONE Bio now represents a viable alternative to US investors seeking to invest in the growth of the Asia Pacific region but wanting a strong US domestic management team coupled with Asian operational expertise. We have now set the foundation for strong organic growth and continue to seek strategic acquisitions," stated Marius Silvasan, ONE's CEO.

"Our Q3 GAAP results only partly reflect the operational performance of the businesses we acquired in the past 5 months since for accounting purposes we can only start booking the revenue and benefit of the net income of the companies acquired starting from the date of each acquisition. For this reason we have elected to show our investors pro-forma results which include historical financial performance for each business on a consolidated basis. In the fourth quarter of 2009 ONE will derive full operational benefits of all acquired businesses," added Mr. Silvasan.

About ONE Bio, Corp.

ONE Bio, Corp. ("ONE") (OTCBB: ONBI) ( headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information